| Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin | Frank Vinluan | 10/14/20 | Boston |
| SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D | Frank Vinluan | 10/12/20 | Boston |
| Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More | Frank Vinluan | 10/09/20 | National |
| Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs | Frank Vinluan | 10/06/20 | Boston |
| Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity | Mandy Jackson | 10/02/20 | National |
| Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China | Frank Vinluan | 09/30/20 | New York |
| Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal | Frank Vinluan | 09/21/20 | San Francisco |
| Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More | Frank Vinluan | 09/18/20 | National |
| Now Closer to Clinical Trials, Codiak BioSciences Refiles IPO Plans | Frank Vinluan | 09/10/20 | Boston |
| Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue | Frank Vinluan | 09/09/20 | National |
| FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures | Frank Vinluan | 09/05/20 | Boston |
| AbbVie Strikes Deal for I-Mab Drug With a Potential Edge in CD47 Chase | Frank Vinluan | 09/04/20 | National |
| Gilead Sciences Places $120M Bet on a Jounce Therapeutics Cancer Drug | Frank Vinluan | 09/01/20 | San Francisco |
| AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial | Sarah de Crescenzo | 08/27/20 | New York |
| Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More | Sarah de Crescenzo | 08/21/20 | National |
| Harmony Bio and Inhibrx Raise Combined $247M in Public Market Debuts | Sarah de Crescenzo | 08/20/20 | National |
| Tango Therapeutics Adds $175M, Deal Turns Partner Gilead Into Investor | Sarah de Crescenzo | 08/17/20 | Boston |
| Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy | Sarah de Crescenzo | 08/17/20 | New York |
| CureVac’s IPO Hauls In $213M as Key mRNA COVID-19 Vaccine Test Nears | Frank Vinluan | 08/14/20 | Europe |
| Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia | Sarah de Crescenzo | 08/12/20 | San Francisco |
| GlaxoSmithKline Multiple Myeloma Drug Earns FDA’s First Anti-BCMA Nod | Sarah de Crescenzo | 08/06/20 | National |
| GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology | Frank Vinluan | 08/05/20 | Boston |
| Kymera Therapeutics Unveils IPO Pitch for Protein Degradation | Frank Vinluan | 07/31/20 | Boston |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Amid Boom Days for Biotech, Inhibrx Lines Up Another IPO Effort | Sarah de Crescenzo | 07/29/20 | San Diego |
| Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test | Sarah de Crescenzo | 07/29/20 | National |
| Gilead Gets Another CAR-T Approval, This Time for Mantle Cell Lymphoma | Frank Vinluan | 07/24/20 | San Francisco |
| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| Amgen Doubles Down on BeiGene Collaboration, Investing $421M More | Sarah de Crescenzo | 07/13/20 | San Francisco |
| 3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments | Sarah de Crescenzo | 07/13/20 | National |
